UBS analyst Dan Leonard raised the firm’s price target on Natera to $104 from $70 and keeps a Buy rating on the shares. The firm has a positive view of the company’s growth opportunities in minimal residual disease testing across multiple indications, as well as its continued leading position in reproductive health testing, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Natera announces next phase of CareDx patent infringement litigation
- Canaccord bullish on Natera growth potential as Medicare extends coverage
- Medicare extends coverage of Natera’s signatera MRD test to ovarian cancer
- NTRA Earnings this Week: How Will it Perform?
- Natera downgraded to Outperform from Strong Buy at Raymond James
